eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

Interleukins 30 and 27 in psoriasis and inflammation

Marianna Majchrzycka
1
,
Joanna Wegner
2
,
Zygmunt Adamski
1
,
Dorota Jenerowicz
1

  1. Department of Dermatology, University Clinical Hospital, Poznan, Poland
  2. Department of Dermatology, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2025.147548
Online publish date: 2025/02/09
Article file
- Interleukins 30.pdf  [0.15 MB]
Get citation
 
 
1. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 2015; 33 (5 Suppl 93): S2-6.
2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397: 1301-5.
3. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL30. J Immunol 2012; 188: 3709-15.
4. Min B, Kim D, Feige MJ. IL-30 (IL-27A): a familiar stranger in immunity, inflammation, and cancer. Exp Mol Med 2021; 53: 823-34.
5. Meka RR, Venkatesha SH, Dudics S, et al. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 2015; 14: 1131-41.
6. Kourko O, Seaver K, Odoardi N, et al. IL-27, IL-30, and IL-35: a cytokine triumvirate in cancer. Front Oncol 2019; 9: 969.
7. Zhang J, Liu X, Huang N, et al. Soluble expression and purification of the functional interleukin-30 protein in Escherichia coli. Prep Biochem Biotechnol 2016; 46: 539-45.
8. Omar NS, Long X, Xian J, et al. Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study. J Int Med Res 2021; 49: 03000605211004039.
9. Park J, DeLong JH, Knox JJ, et al. Impact of interleukin-27p28 on T and B cell responses during toxoplasmosis. Infect Immun 2019; 87: e00455-19.
10. Suzuki M, Yokota M, Ozaki S, Matsumoto T. Intranasal administration of IL-27 ameliorates nasal allergic responses and symptoms. Int Arch Allergy Immunol 2019; 178: 101-5.
11. Jankowski M, Wandtke T. Interleukin-27: Biological Properties and Clinical Application. In: SpringerBriefs in Immunology. Cham: Springer International Publishing 2016.
12. Airoldi I, Cocco C, Sorrentino C, et al. Interleukin-30 promotes breast cancer growth and progression. Cancer Res 2016; 76: 6218-29.
13. Zhu J, Liu JQ, Shi M, et al. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight 2018; 3: e98745.
14. Liu Z, Liu JQ, Shi Y, et al. Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth. Oncoimmunology 2015; 4: e989137.
15. Liu X, Wang Z, Ye N, et al. A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. Biochem Biophys Res Commun 2013; 435:
16. 306-12.
17. EL-Komy MH, Ahmed H, Mourad A, et al. Interleukin 27 in psoriasis: friend or foe? Indian J Dermatol Venereol Leprol 2022; 88: 843-5.
18. Shibata S, Tada Y, Kanda N, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Investig Dermatol 2010; 130: 1034-9.
19. Shibata S, Tada Y, Asano Y, et al. IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. J Investig Dermatol 2013; 133: 479-88.
20. Chen W, Gong Y, Zhang X, et al. Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model. J Dermatol Sci 2017; 85: 115-23.
21. Michalak-Stoma A, Bartosiñska J, Raczkiewicz D, et al. Multiple cytokine analysis of Th1/Th2/Th9/Th17/Th22/Treg cytokine pathway for individual immune profile assessment in patients with psoriasis. Med Sci Monit 2022; 28: e938277.
22. Agarwal D, Singh Tomar S, Alam A, Mishra P. Evaluation of serum interleukin-30 level in patients with psoriasis. J Cardiovasc Dis Res 2022; 13: 3220-4.
23. Atta S. Association of serum IL-30 and soluble GP130 with the risk of psoriasis vulgaris. Eur J Immunol 2024; 31: 61-70.
24. Liu X, Hu Z, Zhang J, et al. IL-30 ameliorates imiquimod and K14-VEGF induced psoriasis-like disease by inhibiting both innate and adaptive immunity disorders. Biochem Biophys Res Commun 2021; 579: 97-104.
25. Blahoianu MA, Rahimi AAR, Kozlowski M, et al. IFN-g-induced IL-27 and IL-27p28 expression are differentially regulated through JNK MAPK and PI3K pathways independent of Jak/STAT in human monocytic cells. Immunobiology 2014; 219: 1-8.
26. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677-87.
27. Czerwiñska J, Owczarczyk-Saczonek A. The role of the neutrophilic network in the pathogenesis of psoriasis. Int J Mol Sci 2022; 23: 1840.
28. Crabé S, Guay-Giroux A, Tormo AJ, et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling1.
29. J Immunol 2009; 183: 7692-702.
30. Tormo AJ, Meliani Y, Beaupré LA, et al. The composite cytokine p28/cytokine-like factor 1 sustains B cell proliferation and promotes plasma cell differentiation. J Immunol 2013; 191: 1657-65.
31. Chong WP, Horai R, Mattapallil MJ, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun 2014; 50: 12-22.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.